中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

16 records (took 0.027 seconds)

    Dynamic of sFlt-1 or endoglin/PLGF ratio as an indicator for imminent preeclampsia and/or HELLP syndrome
    5.
    发明授权
    Dynamic of sFlt-1 or endoglin/PLGF ratio as an indicator for imminent preeclampsia and/or HELLP syndrome 有权

    公开(公告)号：US10302657B2

    公开(公告)日：2019-05-28

    申请号：US14264377

    申请日：2014-04-29

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Barbara Denk ,  Martin Hund

    IPC: G01N33/574 ,  G01N33/68 ,  G01N33/74

    Abstract: Diagnostic methods and tools relating to diagnosing whether a pregnant subject is at risk for developing preeclampsia and/or early-onset preeclampsia within a short period of time. The methods include determining the amounts of the biomarkers sFlt-1 or Endoglin and PIGF in a first and a second sample of said subject, said first sample being obtained prior to said second sample; calculating a first ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the first sample, and a second ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the second sample; and comparing the value of the first and the second ratio, whereby a subject being at risk for developing preeclampsia within a short period of time is diagnosed if the value of the second ratio is increased compared to the value of the first ratio by a factor of at least about 3.

    PREDICTION OF PREECLAMPSIA BASED ON IGFBP-7
    7.
    发明申请
    PREDICTION OF PREECLAMPSIA BASED ON IGFBP-7 有权

    公开(公告)号：US20210140971A1

    公开(公告)日：2021-05-13

    申请号：US17152212

    申请日：2021-01-19

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Martin Hund ,  Johann Karl ,  Ursula-Henrike Wienhues-Thelen

    IPC: G01N33/68

    Abstract: The present invention relates to a method for assessing whether a pregnant subject is at risk of developing preeclampsia or a preeclampsia-related condition, or not, said method comprising the steps of determining the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject, and comparing the determined amount of the biomarker to a reference. Further, the present invention relates to the in vitro use of the biomarker IGFBP-7, or of at least one detection agent which specifically binds to IGFBP-7 in a sample of a pregnant subject for assessing whether said subject is at risk of developing preeclampsia or a preeclampsia-related condition, or not. Also encompassed by the present invention is a device adapted to carry out the method of the present invention.

    MEANS AMD METHODS APPLYING sFlt-1/PIGF OR ENDOGLIN/PIGF RATIO TO RULE OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD
    8.
    发明申请
    MEANS AMD METHODS APPLYING sFlt-1/PIGF OR ENDOGLIN/PIGF RATIO TO RULE OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD 审中-公开
    意味着在某些时间段内应用sFlt-1 / PIGF或EndogLIN / PIGF比例的AMD方法可以排除前列腺素

    公开(公告)号：US20150338415A1

    公开(公告)日：2015-11-26

    申请号：US14576944

    申请日：2014-12-19

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Martin Hund ,  Maria Schoedl

    IPC: G01N33/68 ,  G06F19/00

    CPC classification number: G01N33/689 ,  G01N2333/475 ,  G01N2333/515 ,  G01N2333/71 ,  G01N2333/912 ,  G01N2800/368 ,  G16H50/30 ,  G16H50/70

    Abstract: The present invention concerns the field of diagnostic assays for prenatal diagnosis of preeclampsia. In particular, it relates to a method for diagnosing whether a pregnant subject is not at risk for preeclampsia within a short window of time comprising a) determining the amount of at least one angiogenesis biomarker selected from the group consisting of sFlt-1, Endoglin and PlGF in a sample of said subject, and b) comparing the amount with a reference, whereby a subject being not at risk for developing preeclampsia within a short period of time is diagnosed if the amount is identical or decreased compared to the reference in the cases of sFlt-1 and Endoglin and identical or increased in the case of PlGF, wherein said reference allows for making the diagnosis with a negative predictive value of at least about 98%. Further contemplates are devices and kits for carrying out said method.

    Abstract translation: 本发明涉及先兆子痫产前诊断的诊断测定领域。 特别地，本发明涉及一种用于诊断怀孕受试者在短时间内是否不存在先兆子痫风险的方法，其包括：a）确定选自下组的至少一种血管发生生物标志物的量：sFlt-1，Endoglin和 所述受试者的样本中的PlGF，以及b）将所述量与参考文献进行比较，由此诊断在短时间内不处于发生先兆子痫风险的受试者，如果与所述受试者的参考相比，所述量相同或减少 的sFlt-1和Endoglin，并且在PlGF的情况下相同或增加，其中所述参考文献允许以至少约98％的阴性预测值进行诊断。 进一步考虑的是用于执行所述方法的装置和套件。

    PREDICTION OF POSTPARTUM HELLP SYNDROME, POSTPARTUM ECLAMPSIA OR POSTPARTUM PREECLAMPSIA
    10.
    发明申请
    PREDICTION OF POSTPARTUM HELLP SYNDROME, POSTPARTUM ECLAMPSIA OR POSTPARTUM PREECLAMPSIA 审中-公开

    公开(公告)号：US20200378981A1

    公开(公告)日：2020-12-03

    申请号：US16998444

    申请日：2020-08-20

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Martin Hund ,  Thomas Dieterle ,  Olav Lapaire

    IPC: G01N33/68

    Abstract: The present invention is directed to a method for predicting the risk of a female subject to develop postpartum HELLP syndrome, postpartum preeclampsia, or postpartum eclampsia. The method is based on the determination of the levels of i) sFlt-1 and PlGF, or ii) Endoglin and PlGF in a first sample obtained from said subject before delivery of baby, and a second sample of from said subject obtained after delivery of baby. Moreover, encompassed by the invention are devices and kits for carrying out the method of the present invention.

Patent Agency Ranking